PriceTargets.com logo

Sotera Health - SHC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.50
  • Forecasted Upside: 15.22%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$14.32 As of 05/26/2023 09:47 PM ET
▲ +0.2 (1.42%)

This chart shows the closing price for SHC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sotera Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SHC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SHC

Analyst Price Target is $16.50
▲ +15.22% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Sotera Health in the last 3 months. The average price target is $16.50, with a high forecast of $25.00 and a low forecast of $8.00. The average price target represents a 15.22% upside from the last price of $14.32.

This chart shows the closing price for SHC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Sotera Health. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/2/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/31/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/29/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
2/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/28/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/4/2023BarclaysLower Target$21.00 ➝ $20.00Low
4/4/2023BarclaysLower TargetOverweight$22.00 ➝ $21.00Low
3/1/2023Royal Bank of CanadaBoost TargetOutperform$8.00 ➝ $19.00Low
1/23/2023JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$6.00 ➝ $18.00Low
1/10/2023Wolfe ResearchUpgradePeer Perform ➝ Outperform$25.00Low
1/10/2023BarclaysUpgradeUnderweight ➝ Overweight$6.00 ➝ $22.00Low
11/23/2022The Goldman Sachs GroupLower TargetNeutral$9.00 ➝ $8.00Low
11/15/2022BarclaysDowngradeEqual Weight ➝ Underweight$7.00 ➝ $6.00Low
11/3/2022JPMorgan Chase & Co.Lower TargetUnderweight$9.00 ➝ $6.00Low
11/3/2022Royal Bank of CanadaLower TargetOutperform$25.00 ➝ $8.00Low
10/6/2022BarclaysLower TargetEqual Weight$22.00 ➝ $8.00Low
10/5/2022CitigroupDowngradeBuy ➝ Neutral$25.00 ➝ $9.00Low
9/21/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight$26.00 ➝ $9.00Low
9/20/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$23.00 ➝ $9.00Low
7/13/2022BarclaysLower TargetEqual Weight$24.00 ➝ $22.00N/A
6/9/2022Wolfe ResearchDowngradeOutperform ➝ Peer Perform$26.00Medium
4/5/2022Wolfe ResearchInitiated CoverageOutperform$26.00Medium
3/21/2022The Goldman Sachs GroupLower TargetBuy$31.00 ➝ $27.00Low
3/3/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$34.00 ➝ $22.00High
3/2/2022Credit Suisse GroupLower TargetOutperform$31.00 ➝ $28.00High
3/2/2022KeyCorpLower TargetOverweight$33.00 ➝ $30.00High
3/2/2022BarclaysDowngradeOverweight ➝ Equal Weight$24.00High
8/13/2021BarclaysBoost TargetOverweight$30.00 ➝ $32.00High
7/13/2021BarclaysBoost TargetOverweight$29.00 ➝ $30.00Medium
5/25/2021Credit Suisse GroupReiterated RatingBuy$31.00Low
5/14/2021BarclaysLower TargetOverweight$35.00 ➝ $29.00High
3/10/2021KeyCorpBoost TargetOverweight$31.00 ➝ $33.00High
3/2/2021BarclaysInitiated CoverageOverweight$35.00Low
1/13/2021Robert W. BairdInitiated CoverageOutperform$31.00Medium
12/15/2020Smith Barney CitigroupInitiated CoverageBuy$32.00High
12/15/2020KeyCorpInitiated CoverageOverweight$31.00Low
12/15/2020JPMorgan Chase & Co.Initiated CoverageOverweight$35.00High
12/15/2020Jefferies Financial GroupInitiated CoverageBuy$33.50High
12/15/2020Royal Bank of CanadaInitiated CoverageOutperform$31.00High
12/15/2020Credit Suisse GroupInitiated CoverageOutperform$31.00Low
12/15/2020The Goldman Sachs GroupInitiated CoverageBuy$34.00Low
(Data available from 5/29/2018 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/30/2022
  • 7 very positive mentions
  • 13 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
11/29/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
12/29/2022
  • 7 very positive mentions
  • 18 positive mentions
  • 5 negative mentions
  • 3 very negative mentions
Mentions as of
1/28/2023
  • 13 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2023
  • 9 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
3/29/2023
  • 5 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/28/2023
  • 3 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/28/2023

Current Sentiment

  • 3 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Sotera Health logo
Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.
Read More

Today's Range

Now: $14.32
Low: $14.12
High: $14.35

50 Day Range

MA: $16.26
Low: $14.12
High: $18.15

52 Week Range

Now: $14.32
Low: $5.78
High: $24.90

Volume

621,900 shs

Average Volume

1,756,484 shs

Market Capitalization

$4.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.08

Frequently Asked Questions

What sell-side analysts currently cover shares of Sotera Health?

The following Wall Street sell-side analysts have issued research reports on Sotera Health in the last twelve months: Barclays PLC, Citigroup Inc., JPMorgan Chase & Co., Royal Bank of Canada, The Goldman Sachs Group, Inc., TheStreet, and Wolfe Research.
View the latest analyst ratings for SHC.

What is the current price target for Sotera Health?

6 Wall Street analysts have set twelve-month price targets for Sotera Health in the last year. Their average twelve-month price target is $16.50, suggesting a possible upside of 15.2%. Wolfe Research has the highest price target set, predicting SHC will reach $25.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $8.00 for Sotera Health in the next year.
View the latest price targets for SHC.

What is the current consensus analyst rating for Sotera Health?

Sotera Health currently has 3 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SHC will outperform the market and that investors should add to their positions of Sotera Health.
View the latest ratings for SHC.

What other companies compete with Sotera Health?

Other companies that are similar to Sotera Health include Progyny, agilon health, DaVita, Fresenius Medical Care AG & Co. KGaA and ACADIA Pharmaceuticals. Learn More about companies similar to Sotera Health.

How do I contact Sotera Health's investor relations team?

Sotera Health's physical mailing address is 9100 SOUTH HILLS BLVD SUITE 300, BROADVIEW HEIGHTS OH, 44147. The company's listed phone number is 440-262-1410 and its investor relations email address is [email protected]. The official website for Sotera Health is www.soterahealth.com. Learn More about contacing Sotera Health investor relations.